142 related articles for article (PubMed ID: 26927891)
1. Immunostains Used to Subtype Hepatic Adenomas Do Not Distinguish Hepatic Adenomas From Hepatocellular Carcinomas.
Liu L; Shah SS; Naini BV; French S; Wu TT; Torbenson MS; Chandan VS
Am J Surg Pathol; 2016 Aug; 40(8):1062-9. PubMed ID: 26927891
[TBL] [Abstract][Full Text] [Related]
2. Hepatic adenomas with synchronous or metachronous fibrolamellar carcinomas: both are characterized by LFABP loss.
Graham RP; Terracciano LM; Meves A; Vanderboom PM; Dasari S; Yeh MM; Torbenson MS; Cruise MW
Mod Pathol; 2016 Jun; 29(6):607-15. PubMed ID: 27015136
[TBL] [Abstract][Full Text] [Related]
3. Utility of an immunohistochemical panel consisting of glypican-3, heat-shock protein-70, and glutamine synthetase in the distinction of low-grade hepatocellular carcinoma from hepatocellular adenoma.
Lagana SM; Salomao M; Bao F; Moreira RK; Lefkowitch JH; Remotti HE
Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):170-6. PubMed ID: 22914605
[TBL] [Abstract][Full Text] [Related]
4. CRP Versus SAA for Identification of Inflammatory Hepatic Adenomas.
Soon GST; Yasir S; Jain D; Kakar S; Wu TT; Yeh MM; Torbenson MS; Chen ZE
Appl Immunohistochem Mol Morphol; 2023 Oct; 31(9):590-595. PubMed ID: 37698958
[TBL] [Abstract][Full Text] [Related]
5. Combined use of heat-shock protein 70 and glutamine synthetase is useful in the distinction of typical hepatocellular adenoma from atypical hepatocellular neoplasms and well-differentiated hepatocellular carcinoma.
Nguyen TB; Roncalli M; Di Tommaso L; Kakar S
Mod Pathol; 2016 Mar; 29(3):283-92. PubMed ID: 26769138
[TBL] [Abstract][Full Text] [Related]
6. Expression of liver fatty acid binding protein in hepatocellular carcinoma.
Cho SJ; Ferrell LD; Gill RM
Hum Pathol; 2016 Apr; 50():135-9. PubMed ID: 26997447
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular Adenoma in an Infant With Burn-McKeown Syndrome: Report of a Case.
González IA; Surrey LF; Russo P
Pediatr Dev Pathol; 2022; 25(6):668-671. PubMed ID: 36262073
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular adenoma classification: a comparative evaluation of immunohistochemistry and targeted mutational analysis.
Margolskee E; Bao F; de Gonzalez AK; Moreira RK; Lagana S; Sireci AN; Sepulveda AR; Remotti H; Lefkowitch JH; Salomao M
Diagn Pathol; 2016 Mar; 11():27. PubMed ID: 26961851
[TBL] [Abstract][Full Text] [Related]
9. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum.
Shafizadeh N; Ferrell LD; Kakar S
Mod Pathol; 2008 Aug; 21(8):1011-8. PubMed ID: 18536657
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular neoplasms with loss of liver fatty acid binding protein: Clinicopathologic features and molecular profiling.
Joseph NM; Blank A; Shain AH; Gill RM; Umetsu SE; Shafizadeh N; Torbenson MS; Kakar S
Hum Pathol; 2022 Apr; 122():60-71. PubMed ID: 35104461
[TBL] [Abstract][Full Text] [Related]
11. Hepatocellular nodules expressing markers of hepatocellular adenomas in Budd-Chiari syndrome and other rare hepatic vascular disorders.
Sempoux C; Paradis V; Komuta M; Wee A; Calderaro J; Balabaud C; Quaglia A; Bioulac-Sage P
J Hepatol; 2015 Nov; 63(5):1173-80. PubMed ID: 26119687
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic utility and limitations of glutamine synthetase and serum amyloid-associated protein immunohistochemistry in the distinction of focal nodular hyperplasia and inflammatory hepatocellular adenoma.
Joseph NM; Ferrell LD; Jain D; Torbenson MS; Wu TT; Yeh MM; Kakar S
Mod Pathol; 2014 Jan; 27(1):62-72. PubMed ID: 23807780
[TBL] [Abstract][Full Text] [Related]
13. A Limited Immunohistochemical Panel Can Subtype Hepatocellular Adenomas for Routine Practice.
Larson BK; Guindi M
Am J Clin Pathol; 2017 Jun; 147(6):557-570. PubMed ID: 28472207
[TBL] [Abstract][Full Text] [Related]
14. Ki-67 "hot spot" digital analysis is useful in the distinction of hepatic adenomas and well-differentiated hepatocellular carcinomas.
Jones A; Kroneman TN; Blahnik AJ; Graham RP; Mounajjed T; Torbenson MS; Moreira RK
Virchows Arch; 2021 Feb; 478(2):201-207. PubMed ID: 32583014
[TBL] [Abstract][Full Text] [Related]
15. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions.
Wang HL; Anatelli F; Zhai QJ; Adley B; Chuang ST; Yang XJ
Arch Pathol Lab Med; 2008 Nov; 132(11):1723-8. PubMed ID: 18976006
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular adenomas in a large community population, 2000 to 2010: reclassification per current World Health Organization classification and results of long-term follow-up.
Shafizadeh N; Genrich G; Ferrell L; Kakar S
Hum Pathol; 2014 May; 45(5):976-83. PubMed ID: 24746201
[TBL] [Abstract][Full Text] [Related]
17. EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies.
Cai MY; Tong ZT; Zheng F; Liao YJ; Wang Y; Rao HL; Chen YC; Wu QL; Liu YH; Guan XY; Lin MC; Zeng YX; Kung HF; Xie D
Gut; 2011 Jul; 60(7):967-76. PubMed ID: 21330577
[TBL] [Abstract][Full Text] [Related]
18. A triple stain of reticulin, glypican-3, and glutamine synthetase: a useful aid in the diagnosis of liver lesions.
Swanson BJ; Yearsley MM; Marsh W; Frankel WL
Arch Pathol Lab Med; 2015 Apr; 139(4):537-42. PubMed ID: 25822763
[TBL] [Abstract][Full Text] [Related]
19. Malignant transformation of liver fatty acid binding protein-deficient hepatocellular adenomas: histopathologic spectrum of a rare phenomenon.
Putra J; Ferrell LD; Gouw ASH; Paradis V; Rishi A; Sempoux C; Balabaud C; Thung SN; Bioulac-Sage P
Mod Pathol; 2020 Apr; 33(4):665-675. PubMed ID: 31570768
[TBL] [Abstract][Full Text] [Related]
20. Malignant transformation of hepatic adenomas.
Micchelli ST; Vivekanandan P; Boitnott JK; Pawlik TM; Choti MA; Torbenson M
Mod Pathol; 2008 Apr; 21(4):491-7. PubMed ID: 18246041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
